CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference

Rhea-AI Summary

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present at the Emerging Growth Virtual Conference on March 17-18, 2021. The event will feature discussions on glioblastoma, with Climaco participating in a panel on March 17 from 9:30-10:30 am ET. CNS is focused on developing treatments for brain and central nervous system cancers, including their lead drug candidate, Berubicin, aimed at glioblastoma multiforme. CNS plans to initiate a Phase 2 trial for Berubicin in the U.S. in 2021.

HOUSTON, March 15, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the inaugural Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC. The conference will take place virtually on March 17^th  and 18^th and will feature roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A, and presentations from hundreds of issuers both domestically and internationally.

In addition to the presentation, Mr. Climaco will participate in a live glioblastoma panel discussion on Wednesday, March 17^th from 9:30-10:30 am ET.

Interested parties are invited to attend the virtual conference and access exclusive content by becoming an M-Vest member and registering HERE. To learn more about the event, please visit the conference website: Emerging Growth Virtual Conference.

About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. During 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial (with extensive PK) in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

For more information, please visit www.CNSPharma.com.

About M Vest LLC
M Vest LLC is an online investment bank and digital community built for issuers, investors, and thought leaders to share information and access investment opportunities through capital raisings of Regulation D and Regulation A Offerings.  Founded in 2017 and headquartered in New York City, M-Vest provides insights on current equity market trends, hosts presentations from public companies, and provides access to capital for emerging growth companies. M-Vest hosts live conferences and webinars featuring CEOs discussing the latest developments in their industries. M Vest LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC), is a member of FINRA and SIPC, and is a sister company of Maxim Group, LLC. 

About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB). Member of FINRA SIPC, and NASDAQ. To learn more about Maxim Group, visit maximgrp.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-inaugural-emerging-growth-virtual-conference-301246814.html

SOURCE CNS Pharmaceuticals, Inc.

FAQ

What is CNS Pharmaceuticals presenting at the Emerging Growth Virtual Conference?

CNS Pharmaceuticals will have CEO John Climaco presenting on the company's developments and participating in a glioblastoma panel.

When will CNS Pharmaceuticals participate in the Emerging Growth Virtual Conference?

CNS Pharmaceuticals will participate in the conference on March 17-18, 2021.

What is the focus of CNS Pharmaceuticals' drug Berubicin?

Berubicin is focused on treating glioblastoma multiforme, an aggressive form of brain cancer.

What clinical trials is CNS Pharmaceuticals planning for Berubicin in 2021?

CNS Pharmaceuticals plans to commence a Phase 2 clinical trial of Berubicin for glioblastoma in the U.S. in 2021.

How effective was Berubicin in previous trials?

In a completed Phase 1 trial, Berubicin showed a 44% overall response rate for patients with malignant brain tumors.